Notably, our DEU analysis identified RUNX3 among the most significant DEUs between ASXL1 mutant and control samples in both BOS blood (Fig. 4B) and AML-ASXL1 blood samples (Fig. 4D). Here, ASXL1 is linked to acute myeloid leukemia.